FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review
Stealth Bio has cut 30% of its workforce as it eyes a resubmission based on discussions with the FDA.
Stealth Bio has cut 30% of its workforce as it eyes a resubmission based on discussions with the FDA.
What's Your Reaction?
